POINT Biopharma Global Inc. (PNT) NASDAQ
$12.50 0.02 (0.16%)
Market Cap: $1.33B
As of 12/26/23 04:00 PM EST. Market closed.
POINT Biopharma Global Inc. (PNT)
NASDAQ
$12.50
0.02 (0.16%)
Market Cap: $1.33B
As of 12/26/23 04:00 PM EST. Market closed.
Add to Portfolio
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joe A. McCann Ph.D.
Full Time Employees
129
CEO Compensation (Base)
$479,917
CEO Compensation (Total)
$2.84M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joe A. McCann Ph.D.
Full Time Employees
129
CEO Compensation (Base)
$479,917
CEO Compensation (Total)
$2.84M
Address
4850 West 78th Street, IN, Indianapolis, 46268.
PRICE CHART FOR POINT BIOPHARMA GLOBAL INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$12.50
Previous Close
$12.48
Days Range
$12.49 - $12.51
52 week range
$6.57 - $14.35
Volume
3,290,875
Avg. Volume (30 days)
3,849,591
Market Cap
$1.33B
Dividend Yield
-
P/E
11.36
Shares Outstanding
106,569,000
Open
$12.50
Previous Close
$12.48
Days Range
$12.49 - $12.51
52 week range
$6.57 - $14.35
Volume
3,290,875
Avg. Volume (30 days)
3,849,591
Market Cap
$1.33B
Dividend Yield
-
P/E
11.36
Shares Outstanding
106,569,000
FINANCIAL STATEMENTS FOR POINT BIOPHARMA GLOBAL INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR POINT BIOPHARMA GLOBAL INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| BVF PARTNERS L P/IL | Former 10% Owner | Dec 18, 2023 | Sale | $12.45 | 17,161,278 | 213,657,908 | 0 | Dec 20, 2023, 06:09 PM |
| HOGUE GERALD L. | Director | Mar 21, 2023 | Option Exercise | $6.97 | 17,936 | 125,014 | 21,596 | Mar 23, 2023, 08:09 PM |
| MCCANN JOE A. | Chief Executive Officer | Nov 29, 2022 | Buy | $6.64 | 2,160 | 14,342 | 3,616,313 | Nov 30, 2022, 07:56 PM |
| Lubner David Charles | Director | Nov 23, 2022 | Buy | $6.85 | 3,600 | 24,660 | 3,600 | Nov 28, 2022, 04:03 PM |
| HOGUE GERALD L. | Director | Nov 25, 2022 | Buy | $6.82 | 3,660 | 24,943 | 3,660 | Nov 28, 2022, 04:02 PM |
| Malik Rajesh | Director | Nov 28, 2022 | Buy | $6.66 | 3,700 | 24,642 | 3,700 | Nov 28, 2022, 04:01 PM |
| MARGOLIN YAEL | Director | Nov 21, 2022 | Buy | $6.56 | 1,710 | 11,218 | 1,710 | Nov 23, 2022, 12:43 PM |
| GOODMAN JONATHAN R. | Director | Nov 18, 2022 | Buy | $6.33 | 6,000 | 37,980 | 41,872 | Nov 21, 2022, 05:54 PM |
| SILBER ALLAN C | Executive Chairman | Nov 18, 2022 | Buy | $6.50 | 22,397 | 145,581 | 4,268,605 | Nov 21, 2022, 05:52 PM |
| SILBER ALLAN C | Executive Chairman | Nov 17, 2022 | Buy | $6.00 | 27,603 | 165,618 | 4,246,208 | Nov 21, 2022, 05:52 PM |
| FLESHNER NEIL E. | Chief Medical Officer | May 25, 2022 | Sale | $7.51 | 564,204 | 4,237,172 | 3,023,045 | May 26, 2022, 04:05 PM |
| Kolchinsky Peter | Chief Executive Officer | Jun 29, 2021 | Option Exercise | $10.00 | 209,100 | 2,091,000 | 1,098,318 | Jun 30, 2021, 04:31 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Jun 29, 2021 | Buy | $10.00 | 209,100 | 2,091,000 | 1,098,318 | Jun 30, 2021, 04:30 PM |
| Kolchinsky Peter | Chief Executive Officer | Jun 24, 2021 | Option Exercise | $10.00 | 889,218 | 8,892,180 | 889,218 | Jun 24, 2021, 07:08 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| BVF PARTNERS L P/IL | Former 10% Owner | 12/18/2023 | 213,657,908 |
| HOGUE GERALD L. | Director | 03/21/2023 | 125,014 |
| MCCANN JOE A. | Chief Executive Officer | 11/29/2022 | 14,342 |
| Lubner David Charles | Director | 11/23/2022 | 24,660 |
| HOGUE GERALD L. | Director | 11/25/2022 | 24,943 |
| Malik Rajesh | Director | 11/28/2022 | 24,642 |
| MARGOLIN YAEL | Director | 11/21/2022 | 11,218 |
| GOODMAN JONATHAN R. | Director | 11/18/2022 | 37,980 |
| SILBER ALLAN C | Executive Chairman | 11/18/2022 | 145,581 |
| SILBER ALLAN C | Executive Chairman | 11/17/2022 | 165,618 |
| FLESHNER NEIL E. | Chief Medical Officer | 05/25/2022 | 4,237,172 |
| Kolchinsky Peter | Chief Executive Officer | 06/29/2021 | 2,091,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 06/29/2021 | 2,091,000 |
| Kolchinsky Peter | Chief Executive Officer | 06/24/2021 | 8,892,180 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR POINT BIOPHARMA GLOBAL INC.
STOCK BUYBACKS FOR POINT BIOPHARMA GLOBAL INC.
Load More
Period of Report: 06/30/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2023
0.06%
1Q
12/31/2022
-5.15%
2Q
09/30/2022
14.42%
3Q
06/30/2022
17.31%
4Q
03/31/2022
17.31%
5Q
12/31/2021
43.16%
6Q
09/30/2021
17.31%
7Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR POINT BIOPHARMA GLOBAL INC.
LOADING...